On September 6, 2023 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, reported its participation in two investor conferences in September 2023 (Press release, Citius Pharmaceuticals, SEP 6, 2023, View Source [SID1234634958]). Citius Chairman and CEO Leonard Mazur will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, and at the Sidoti Small-Cap Virtual Conference on Wednesday, September 20, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Conference Details:

Presentation:

2:00 pm ET on September 11, 2023

Location:

Lotte New York Palace Hotel, New York City

Registration:

Available on the conference website.

1×1 meetings:

Requests available upon registration or by contacting Citius Investor Relations.

Webcast:

Join live.

Sidoti Conference Details:

Presentation:

2:30 pm ET on September 20, 2023

Location:

Virtual

Registration:

Available on the conference website.

1×1 meetings:

Requests available through a Sidoti representative.

On September 6, 2023 XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, reported that Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET (Press release, Xoma, SEP 6, 2023, View Source [SID1234634957]). The conference is being held in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation can be accessed at https://bit.ly/3qJMUgT or by visiting the investor relations section of the company’s website at www.xoma.com. A replay of the conversation will be available and archived on the site for 90 days after the event.

On September 6, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, reported abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma (Press release, Harpoon Therapeutics, SEP 6, 2023, View Source [SID1234634956]). The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the IMS poster presentation are as follows:

Title: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
Poster Number: P-292
Presenter: Sumit Madan, M.D., Banner MD Anderson Cancer Center
Session/Location: Poster Session 2, Trianti Hall Level II Foyer
Date: Thursday, September 28
Time: Viewing – 10:00 to 18:15 EEST / 3:00 a.m. to 1:15 p.m. ET, Presentation – 12:30 to 13:30 EEST / 5:30 a.m. to 6:30 a.m. ET

The poster will also be available on Harpoon’s website following the presentation.

For more details about the IMS Annual Meeting, please visit:
View Source;sortMenu=101000

On September 6, 2023 Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 (Press release, Onconova, SEP 6, 2023, View Source [SID1234634955]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Date/Time:
Monday, September 11, 2023, available on-line beginning at 7:00 AM ET
Speaker: Steven Fruchtman, M.D., President & CEO
Investor Access: Webcast Link
1X1 meetings The Onconova Management Team will be available for 1X1 meetings during the conference. Those interested in requesting a meeting should contact their H.C. Wainwright representative.

The presentation can be viewed here or on the "Corporate Events and Presentations" section of the Onconova website and will be archived for 90 days.

On September 6, 2023 Moderna, Inc. (Nasdaq:MRNA), reported its participation in a fireside chat at Morgan Stanley’s 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET (Press release, Moderna Therapeutics, SEP 6, 2023, View Source [SID1234634954]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.